Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie announced that upadacitinib (15 mg and 30 mg) met co-primary endpoints in the Phase 3 Measure Up 1 study for treating moderate to severe atopic dermatitis in adults and adolescents. At week 16, 70% and 80% of patients achieved EASI 75 with upadacitinib versus 16% in the placebo group. Additionally, 48% and 62% achieved vIGA-AD scores of clear or almost clear. Significant and rapid reductions in itch were also noted, with no new safety risks compared to existing data for RINVOQ. Full results will be shared in future medical forums.
On June 17, 2020, AbbVie (NYSE: ABBV) declared a quarterly cash dividend of $1.18 per share, payable on August 14, 2020 to stockholders of record as of July 15, 2020. Since its inception in 2013, AbbVie has increased its dividend by 195 percent. The company is a member of the S&P Dividend Aristocrats Index, recognizing firms that have raised dividends for at least 25 consecutive years. AbbVie's mission focuses on innovative medicines across various therapeutic areas, including immunology and oncology.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has received FDA approval for JUVÉDERM® VOLUMA™ XC, the first and only injectable filler for chin augmentation in adults over 21. This approval adds to its existing indication for cheek augmentation, enhancing its market presence as the leading product in the JUVÉDERM® portfolio. The clinical study demonstrated its safety and efficacy, with high patient satisfaction reported. This innovation reflects Allergan's commitment to meeting the growing demand for facial symmetry and harmony among patients.